Mangalam Drugs Q2 FY27 Unaudited Results: Net Loss Widens, Going Concern Uncertainty Highlighted
Mangalam Drugs reported its Q2 FY27 unaudited results. The company posted a consolidated net loss of ₹2.08 crore for the quarter and ₹14.85 crore for the half-year ended September 30, 2026. Standalone net loss was ₹7.21 crore for the quarter and ₹14.76 crore for the half-year. A material uncertainty regarding the company's ability to continue as a going concern was highlighted due to NPA classification and a demand notice from Bank of Baroda.
The declaration of a material uncertainty regarding the company's ability to continue as a going concern, coupled with increasing losses, has a significant impact on investor confidence and the company's future prospects.
The company reported widening losses on both consolidated and standalone bases, and a material uncertainty regarding its ability to continue as a going concern was highlighted in the auditor's report.
Mangalam Drugs and Organics Limited announced the outcome of its Board Meeting held on November 5, 2026. The Board approved the Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026. The company reported a net loss for the period.
The unaudited consolidated financial results for the quarter ended September 30, 2026, show a net loss of ₹2.08 crore, compared to a net loss of ₹0.74 crore in the same quarter last year. For the half-year ended September 30, 2026, the consolidated net loss stood at ₹14.85 crore, an increase from ₹4.38 crore in the corresponding period of the previous year.
On a standalone basis, the net loss for the quarter ended September 30, 2026, was ₹7.21 crore, a significant increase from ₹1.25 crore in the same quarter last year. The standalone net loss for the half-year ended September 30, 2026, was ₹14.76 crore, compared to ₹2.01 crore in the prior year period.
The Limited Review Report highlighted a material uncertainty regarding the company's ability to continue as a going concern. This is due to the classification of borrowings from two consortium banks as Non-Performing Assets (NPAs) since January 2026, a demand notice from Bank of Baroda under the SARFAESI Act, and current liabilities exceeding current assets by ₹4,521.21 lakh as of September 30, 2026. The company is in discussions with lenders to resolve the debt. Despite these concerns, the Board considers it appropriate to prepare the financial results on a going concern basis, citing the company's net worth, continuing operations, and ongoing discussions with lenders.
What to do with a filing like this
Mangalam Drugs And Organics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mangalam Drugs And Organics Limited. Read the original for the full detail.